Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26337928 | 0.83 | GRM2 (0.59) | LMNASMN1; SMN2KMT2AGRM2PKM | |
| SCHEMBL30679003 | 0.83 | GRM2 (0.59) | LMNASMN1; SMN2KMT2AGRM2PKM | |
| SCHEMBL12728853 | 0.80 | KDM4E (0.73) | KDM4EHTTMAPTLMNASMN1; SMN2 | |
| SCHEMBL4152030 | 0.76 | GRM2 (0.75) | KDM4EHTTMAPTLMNASMN1; SMN2 | |
| SCHEMBL31183018 | 0.75 | MEN1 (0.68) | KDM4EHTTMAPTLMNASMN1; SMN2 | |
| SCHEMBL4155796 | 0.75 | MEN1 (0.68) | KDM4EHTTMAPTLMNASMN1; SMN2 | |
| SCHEMBL2900203 | 0.74 | MEN1 (0.66) | KDM4EHTTMAPTLMNASMN1; SMN2 | |
| SCHEMBL20371574 | 0.74 | KDM4E (0.68) | KDM4EHTTMAPTLMNASMN1; SMN2 | |
| Iodide SCHEMBL2892303 | 0.73 | MEN1 (0.64) | KDM4EHTTMAPTLMNASMN1; SMN2 | |
| Iodide SCHEMBL2900263 | 0.73 | MEN1 (0.64) | KDM4EHTTMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-20210284617-A1 | Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof | AMGEN INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210284617-A1 | Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof | AMGEN INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3494108-B1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AMGEN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3494108-A1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Amgen Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018027021-A1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AMGEN INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284617-A1 | Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof | EPOR, KDM5A, PSMA5 | KDM4E 24/4885HTT 3848/4885MAPT 4106/4885 |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | EPOR, KDM5A, PSMA5 | KDM4E 24/4885HTT 3848/4885MAPT 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.